C&R Research Inc is a Korea-based company is mainly engaged in the clinical trial agency and drug development business. The Company is mainly engaged in the provision of comprehensive early-stage clinical services in the areas of medical writing, regulatory matters, data management, biostatistics and others. The Company is mainly engaged in the provision of consulting services including initial clinical development, clinical trial development, global clinical trial development and others. In addition, the Company is also engaged in the operation of clinical trial training center.

Employees

486

Sector

Biotechnology & Medical Research

Calendar

Dec. 29 Ex-dividend date - 50 KRW

More about the company

Quotes

Date	Price	Change	Volume
26-11-13	₩2,095.00	+7.22%	69,132
26-11-12	₩1,954.00	-2.10%	3,995
26-11-11	₩1,996.00	0.00%	3,036
26-11-10	₩1,996.00	-0.05%	4,077
26-11-09	₩1,997.00	+2.67%	12,204

End-of-day quote Korea S.E.

More quotes

End-of-day quote Korea S.E. 2026-11-13			5-day change	1st Jan Change
2,095.00 ^KRW	+7.22%		+7.71%	-53.44%

Nov. 03	C&R Research Inc. announces Annual dividend, payable on April 09, 2027	CI
Mar. 30	C&R Research Inc wins 11.5 billion won order	RE

Market Cap	24.08B 18.01M 16.32M 15.1M 13.62M 25.67M 1.7B 26.57M 181M 71.91M 907M 67.59M 66.16M 2.88B	P/E 2024	17.1x	P/E 2025	20x
Enterprise Value	21.4B 16.01M 14.51M 13.42M 12.11M 22.82M 1.51B 23.62M 161M 63.93M 806M 60.09M 58.81M 2.56B	EV / Sales 2024	0.98x	EV / Sales 2025	0.75x
Free-Float	36.73%	Yield 2024	0.86%	Yield 2025	1.11%

Nov. 03	C&R Research Inc. announces Annual dividend, payable on April 09, 2027	CI
Mar. 30	C&R Research Inc wins 11.5 billion won order	RE
Nov. 05	C&R Research Inc. announces Annual dividend, payable on April 13, 2026	CI
23-03-22	C&R Research Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
21-12-07	C&R Research Co., Ltd. completed the acquisition of NH Special Purpose Acquisition 17 Company in a reverse merger transaction.	CI
21-06-22	C&R Research Co., Ltd. signed an agreement to acquire NH Special Purpose Acquisition 17 Company in a reverse merger transaction.	CI
20-09-17	Nh Special Purpose Acquisition 17 Company has completed an IPO in the amount of KRW 12 billion.	CI
20-07-01	Nh Special Purpose Acquisition 17 Company has filed an IPO.	CI

1 day	+7.22%
1 week	+6.72%
Current month	-1.18%
1 month	-8.11%
3 months	+5.81%
6 months	-39.54%
Current year	-53.44%

C&R Research Inc. Stock

Stocks

A359090

KR7359090008

Biotechnology & Medical Research

Valuation: C&R Research Inc.

Chart: C&R Research Inc.

Latest news: C&R Research Inc.

Press Releases: C&R Research Inc.

Quotes and Performance

Price Extremes

Managers and Directors: C&R Research Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

1 week	1,910	2,140
1 month	1,880	2,390
Current year	1,667	4,870
1 year	1,667	5,890
3 years	1,667	11,975
5 years	1,667	13,400
10 years	1,667	13,400

Manager	Title	Age	Since
Moon-Tae Yoon CEO	Chief Executive Officer	75	2021-12-07
Kyu-Sun Moon DFI	Director of Finance/CFO	49	-
Byeong-in Ahn PSD	President	56	-

Director	Title	Age	Since
Moon-Tae Yoon BRD	Director/Board Member	75	2021-12-07
Jung-Hee Park BRD	Director/Board Member	62	2021-10-27
Byeong-in Ahn BRD	Director/Board Member	56	-

Date	Insider	Type	Quantity	% Market Cap.
12/22/24	Yun-ho Kim	Sell	73,163	0.1290%
9/23/24	Jin-hak Kim	Buy	6,675	0.0118%
9/23/24	Jin-hak Kim	Buy	13,325	0.0236%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
C&R RESEARCH INC.	+7.22%	+6.72%	-52.44%	-65.26%	16.82M
WUXI APPTEC CO., LTD.	-2.69%	-5.28%	+58.42%	+65.89%	68.45B
ARGENX SE	-0.92%	+7.70%	+12.90%	+93.35%	61.31B
LONZA GROUP AG	0.00%	-0.95%	+20.09%	+99.04%	55.73B
BEONE MEDICINES AG	+0.14%	+7.56%	+10.35%	+109.20%	47.51B
IQVIA HOLDINGS INC.	-2.21%	+0.09%	+20.03%	+35.28%	44.68B
REVOLUTION MEDICINES, INC.	-2.30%	-3.02%	+161.72%	+774.12%	38.14B
CELLTRION, INC.	+2.15%	-0.47%	+22.85%	+56.09%	35.85B
GENMAB A/S	-2.32%	-5.14%	+75.43%	+60.15%	33.05B
INSMED INCORPORATED	+2.62%	+11.40%	-37.67%	+410.15%	25.9B
Average	+0.17%	+2.66%	+29.17%	+163.80%	41B
Weighted average by Cap.	-0.86%	+2.25%	+38.48%	+162.35%

	2024	2025
Net sales	59.69B 44.65M 40.46M 37.43M 33.77M 63.64M 4.21B 65.88M 450M 178M 2.25B 168M 164M 7.14B	64.98B 48.61M 44.05M 40.74M 36.76M 69.28M 4.58B 71.72M 489M 194M 2.45B 182M 179M 7.77B
Net income	3.84B 2.87M 2.6M 2.41M 2.17M 4.09M 271M 4.24M 28.91M 11.46M 145M 10.78M 10.55M 459M	2.59B 1.93M 1.75M 1.62M 1.46M 2.76M 182M 2.85M 19.47M 7.72M 97.42M 7.26M 7.1M 309M
Net Debt	-7.67B -5.74M -5.2M -4.81M -4.34M -8.18M -541M -8.47M -57.8M -22.92M -289M -21.54M -21.09M -918M	-2.67B -2M -1.81M -1.68M -1.51M -2.85M -189M -2.95M -20.14M -7.99M -101M -7.51M -7.35M -320M